Clinical and analytical performance of the BD Onclarity HPV Assay with SurePath screening samples from the Danish cervical screening program using the VALGENT framework.
The VALidation of HPV GENotyping Tests (VALGENT) framework is an international cooperation designed to evaluate HPV assays with genotyping capabilities. Here we assessed the performance of the BD Onclarity assay using Danish SurePath cervical screening samples collected under the fourth VALGENT instalment, constituting 998 consecutive samples from a screening population and 297 enriched samples with abnormal cytology (100 ASCUS, 100 LSIL, 97 HSIL). The Onclarity assay individually detects six HPV genotypes (16, 18, 31, 45, 51, 52) and eight genotypes in three bulks (33/58, 56/59/66, 35/39/68). The clinical performance of the Onclarity assay for detection of ≥CIN2 and 2xNILM was assessed relative to that of the GP5+/6+ PCR Enzyme ImmunoAssay (GP-EIA) by a non-inferiority test. The relative sensitivity for ≥CIN2 was 1.00 (95% CI: 0.97-1.04) and relative specificity for 2xNILM was 1.04 (95% CI: 1.02-1.06). The Onclarity assay was found to be non-inferior to GP-EIA for both sensitivity (p=0.0006) and specificity (p<0.0001). The type specific performance of the Onclarity was also assessed, using the GP5+/6+ PCR with Luminex genotyping (GP-LMNX) as comparator. Onclarity showed good concordance for almost all HPV genotypes groups. A stability analysis of SurePath samples was also performed, where a SurePath aliquot was stored for 7 months refrigerated and the internal control of the Onclarity assay was used as a marker for cellularity. The Ct value was the same (24.8) in the first and second Onclarity run (24.8), showing that SurePath samples can be stored refrigerated for 7 months and still remain a valid test specimen.